Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Cellectar Biosciences (NASDAQ: CLRB) announced that it will present interim data from its CLOVER-2 Phase 1b clinical trial at the upcoming AACR Special Conference on Pediatric Cancer in Boston. The presentation will focus on the study of iopofosine I 131 in treating inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG).
The company's abstract has been selected for an oral presentation in a plenary session on September 26, 2025, followed by a 55-minute panel discussion. Chief Operating Officer Jarrod Longcor will present the interim findings, which the company reports as encouraging, suggesting potential clinical benefits for patients with limited treatment options.
Cellectar Biosciences (NASDAQ: CLRB) ha annunciato che presenterà dati provvisori dello studio CLOVER-2 di fase 1b alla prossima Conferenza Speciale AACR sul Cancro Pediatrico a Boston. La presentazione verterà sull'impiego di iopofosine I 131 nel trattamento del glioma pediatrico ad alto grado recidivante o refrattario (r/r pHGG) non operabile.
L'abstract dell'azienda è stato selezionato per una presentazione orale in una sessione plenaria il 26 settembre 2025, seguita da una discussione di panel di 55 minuti. Il Chief Operating Officer Jarrod Longcor presenterà i risultati provvisori, che l'azienda definisce incoraggianti e indicativi di possibili benefici clinici per pazienti con opzioni terapeutiche limitate.
Cellectar Biosciences (NASDAQ: CLRB) anunció que presentará datos provisionales de su ensayo CLOVER-2 de fase 1b en la próxima Conferencia Especial AACR sobre Cáncer Pediátrico en Boston. La presentación se centrará en el estudio de iopofosina I 131 para el tratamiento de glioma pediátrico de alto grado recidivante o refractario (r/r pHGG) inoperable.
El resumen de la compañía fue seleccionado para una presentación oral en una sesión plenaria el 26 de septiembre de 2025, seguida de una discusión en panel de 55 minutos. El Director de Operaciones, Jarrod Longcor, expondrá los resultados provisionales, que la empresa califica de alentadores y que sugieren posibles beneficios clínicos para pacientes con opciones de tratamiento limitadas.
Cellectar Biosciences (NASDAQ: CLRB)는 보스턴에서 열리는 AACR 소아암 특별회의에서 CLOVER-2 1b상 임상시험의 중간 데이터를 발표할 예정이라고 밝혔습니다. 발표는 수술이 불가능한 재발성 또는 불응성 소아 고등급 교모세포종(r/r pHGG)에 대한 iopofosine I 131의 연구에 초점을 맞춥니다.
회사의 초록은 2025년 9월 26일 총회 세션에서의 구두 발표로 선정되었으며, 이어 55분간의 패널 토론이 예정되어 있습니다. 최고운영책임자(COO) Jarrod Longcor가 중간 결과를 발표할 예정이며, 회사는 해당 결과를 고무적이라고 보고하며 치료 옵션이 제한된 환자들에게 잠재적 임상적 이익을 시사한다고 전했습니다.
Cellectar Biosciences (NASDAQ: CLRB) a annoncé qu'elle présentera des données intérimaires de son essai CLOVER-2 de phase 1b lors de la prochaine Conférence spéciale AACR sur le cancer pédiatrique à Boston. La présentation portera sur l'étude de iopofosine I 131 dans le traitement des gliomes pédiatriques de haut grade récurrents ou réfractaires (r/r pHGG) inopérables.
L'abstract de la société a été sélectionné pour une présentation orale en séance plénière le 26 septembre 2025, suivie d'une discussion en panel de 55 minutes. Le directeur des opérations, Jarrod Longcor, présentera les résultats intérimaires que la société qualifie d'encourageants et qui suggèrent des bénéfices cliniques potentiels pour des patients aux options thérapeutiques limitées.
Cellectar Biosciences (NASDAQ: CLRB) gab bekannt, dass das Unternehmen Zwischenergebnisse seiner CLOVER-2 Phase-1b-Studie auf der bevorstehenden AACR Special Conference on Pediatric Cancer in Boston vorstellen wird. Die Präsentation konzentriert sich auf die Untersuchung von iopofosine I 131 zur Behandlung nicht operabler, rezidivierender oder refraktärer pädiatrischer Hochgrad-Gliome (r/r pHGG).
Das Abstract des Unternehmens wurde für eine mündliche Präsentation in einer Plenarsitzung am 26. September 2025 ausgewählt, gefolgt von einer 55‑minütigen Podiumsdiskussion. Chief Operating Officer Jarrod Longcor wird die Zwischenergebnisse vorstellen, die das Unternehmen als ermutigend bezeichnet und die mögliche klinische Vorteile für Patienten mit begrenzten Behandlungsoptionen nahelegen.
- None.
- None.
Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients
FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for oral presentation followed by a 55-minute panel discussion with other experts in this area at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer taking place September 25-28 in Boston, Massachusetts. The oral presentation will highlight interim data from the Phase 1b dose and regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG).
“We are honored that the AACR peer review process has led to the selection of our abstract for a plenary session presentation regarding the treatment of pediatric high-grade glioma patients with iopofosine I 131,” said Jarrod Longcor, chief operating officer of Cellectar. “We are highly encouraged with these initial findings from the CLOVER-2 trial in pediatric patients and believe this outcome further validates the clinical potential of iopofosine I 131 to treat aggressive cancers for patients with limited treatment options.”
| Details of the poster presentation are as follows: | ||
| Title: | “Precision Radiotherapy for Incurable Brain Tumors: Phase 1b Dose & Regimen Optimization Study of Iopofosine I 131 in Inoperable Relapsed or Refractory Pediatric High-Grade Glioma, Interim Data Assessment” | |
| Session: | Plenary Session 3: From Targets to Trials: Rethinking How We Design Child-First Medicine | |
| Track: | Scientific Presentations: Navigating the landscape of paediatric oncology modalities | |
| Date/Time: | September 26, 2025, 2:50 pm Eastern time | |
| Presenter: | Jarrod Longcor | |
About Pediatric High-Grade Gliomas
Pediatric high-grade gliomas are a collection of aggressive tumors affecting the brain and central nervous system. The patients enrolled in CLOVER-2 with pHGG (n=14) were diagnosed with diffuse midline gliomas (DMG), ependymomas, diffuse intrinsic pontine gliomas (DIPG), diffuse hemispheric gliomas (DHG) and anaplastic ependymomas. As reported in the literature, median progression free survival (PFS) and overall survival (OS) for patients with relapsed pHGG is poor; approximately 2.25 months and 5.6 months, respectively. While MRI measures of tumor volume change can be helpful and are used as a surrogate in clinical trials, they often fail to predict survival.
About the CLOVER-2 Trial
The ongoing Phase 1b trial of iopofosine I 131 consists of children, adolescents and young adults with r/r pHGG at multiple sites in the United States and Canada. The study is designed to evaluate the safety and tolerability of iopofosine I 131 in two dosing cohorts, one cohort receiving two doses at 20mCi/m2 each separated by 14 days for two cycles with a third optional cycle. Patients in the second cohort will receive 10 mCi/m2 each, separated by 14 days for three cycles with a fourth optional cycle. The study will also determine therapeutic activity defined as progression free survival (PFS) and overall survival, antitumor activity defined as the reduction in tumor volume and identify the recommended Phase 2/3 dose of iopofosine I 131 in children, adolescents and young adults with r/r pHGG.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarterly period ending June 30, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) present at the AACR Special Conference on Pediatric Cancer 2025?
What will Cellectar Biosciences present at the AACR Special Conference 2025?
Who will present Cellectar's (CLRB) data at the AACR Special Conference?
What type of presentation will Cellectar (CLRB) give at the AACR conference?
